Securities Law
Quantum BioPharma Refutes Securities Law Allegations from Law Firms
Quantum BioPharma Ltd. has formally rejected what it calls vague and unsubstantiated claims by The Schall Law Firm and DJS Law Group regarding alleged securities law violations, stating the announcements appear designed to mislead investors and harm the company's reputation.
Quantum BioPharma Rejects Law Firms' Allegations as Unsubstantiated
Quantum BioPharma Ltd. has formally refuted securities law violation claims from two law firms, calling them vague and unsubstantiated attempts to mislead investors and damage the company's reputation.
Quantum BioPharma Sets Record Date for Litigation-Linked CVR Distribution
Quantum BioPharma has established October 27, 2025 as the record date for distributing contingent value rights that entitle shareholders to a portion of potential litigation recoveries exceeding $700 million from major financial institutions.
Quantum BioPharma Ltd. Challenges Motion to Dismiss in $700 Million Market Manipulation Case
Quantum BioPharma Ltd. opposes a motion to dismiss in a significant lawsuit alleging market manipulation by major financial institutions, highlighting the potential implications for securities law enforcement and investor protection.
Compass Diversified Secures Extended Forbearance Amid Subsidiary Investigation
Compass Diversified extends its forbearance agreement with lenders to October 24, 2025, while increasing its revolving credit facility availability to $60 million, amidst ongoing investigations into financial irregularities at subsidiary Lugano Holdings, Inc.
Crypto Leaders Advocate for Transparency and Regulation to Ensure Market Stability
Industry figures like Barry Silbert are working to establish transparency and regulatory clarity in the cryptocurrency market to protect investors and ensure its long-term success.
US~Observer Investigates Morpheus Research Amid Stock Decline Concerns
The US~Observer is investigating Morpheus Research following reports linked to significant stock drops in several companies, raising questions about market integrity and investor protection.
Quantumzyme Addresses OTC Markets Caveat Emptor Status and Unauthorized Promotional Activity
Biotechnology firm Quantumzyme is taking swift action to address its Caveat Emptor designation from OTC Markets and denounce unauthorized promotional text messages, demonstrating its commitment to regulatory compliance and market integrity.